{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:05:53Z","timestamp":1790741153406,"version":"4.1.0"},"reference-count":20,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2020,3,10]],"date-time":"2020-03-10T00:00:00Z","timestamp":1583798400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Translational Sci"],"published-print":{"date-parts":[[2020,7]]},"abstract":"<jats:p>\n                    Deutetrabenazine (Austedo, Teva Pharmaceuticals) is a deuterated form of tetrabenazine. It is the first deuterated drug to receive US regulatory approval and is approved for treatment of chorea in Huntington\u2019s disease and tardive dyskinesia. Two oral single dose studies comparing deutetrabenazine (25\u00a0mg) with tetrabenazine (25\u00a0mg) in healthy volunteers evaluated the impact of deuteration on pharmacokinetics of the active metabolites, alpha\u2010dihydrotetrabenazine (\u03b1\u2010HTBZ) and beta\u2010dihydrotetrabenazine (\u03b2\u2010HTBZ), metabolite profile, safety, and tolerability. In the two\u2010way, cross\u2010over study, the mean elimination half\u2010life of deuterated total (\u03b1\u00a0+\u00a0\u03b2)\u2010HTBZ was doubled compared with nondeuterated total (\u03b1\u00a0+\u00a0\u03b2)\u2010HTBZ, with a twofold increase in overall mean exposure (area under the concentration\u2010time curve from zero to infinity (AUC\n                    <jats:sub>0\u2013inf<\/jats:sub>\n                    )) and a marginal increase in mean peak plasma concentration (C\n                    <jats:sub>max<\/jats:sub>\n                    ). In the mass balance and metabolite profiling study, there were no novel plasma or urinary metabolites of [\n                    <jats:sup>14<\/jats:sup>\n                    C]\u2010deutetrabenazine relative to [\n                    <jats:sup>14<\/jats:sup>\n                    C]\u2010tetrabenazine. Specific deuteration in deutetrabenazine resulted in a superior pharmacokinetic profile and an increased ratio of active\u2010to\u2010inactive metabolites, attributes considered to provide significant benefits to patients.\n                  <\/jats:p>","DOI":"10.1111\/cts.12754","type":"journal-article","created":{"date-parts":[[2020,3,10]],"date-time":"2020-03-10T12:49:56Z","timestamp":1583844596000},"page":"707-717","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Pharmacokinetic and Metabolic Profile of Deutetrabenazine (TEV\u201050717) Compared With Tetrabenazine in Healthy Volunteers"],"prefix":"10.1111","volume":"13","author":[{"given":"Frank","family":"Schneider","sequence":"first","affiliation":[{"name":"Teva Pharmaceutical Industries, Ratiopharm GmbH Ulm Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Bradbury","sequence":"additional","affiliation":[{"name":"Formerly of Teva Pharmaceuticals Alterity Therapeutics Limited Newark California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.","family":"Baillie","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry School of Pharmacy University of Washington Seattle Washington USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Stamler","sequence":"additional","affiliation":[{"name":"Formerly of Teva Pharmaceuticals Alterity Therapeutics Limited Newark California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Hellriegel","sequence":"additional","affiliation":[{"name":"Teva Pharmaceutical Products R&amp;D, Inc. West Chester Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna S.","family":"Cox","sequence":"additional","affiliation":[{"name":"Formerly of Teva Pharmaceuticals Pfizer Corporation Norristown Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pippa S.","family":"Loupe","sequence":"additional","affiliation":[{"name":"Teva Pharmaceuticals Industries New Orleans Louisiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juha\u2010Matti","family":"Savola","sequence":"additional","affiliation":[{"name":"Teva Pharmaceuticals International GmbH Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Rabinovich\u2010Guilatt","sequence":"additional","affiliation":[{"name":"Teva Pharmaceutical Industries Netanya Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,3,10]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000198586.85250.13"},{"key":"e_1_2_10_3_1","first-page":"545","article-title":"Tetrabenazine in the treatment of Huntington's disease","volume":"3","author":"Paleacu D.","year":"2007","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2011.02.046"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(84)90562-4"},{"key":"e_1_2_10_6_1","first-page":"690","article-title":"Tetrabenazine (Xenazine), an FDA\u2010approved treatment option for Huntington's disease\u2010related chorea","volume":"33","author":"Yero T.","year":"2008","journal-title":"P T"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nucmedbio.2006.05.006"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(01)80109-0"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1159\/000449184"},{"key":"e_1_2_10_10_1","first-page":"GJPPS.MS.ID.555","article-title":"Deuteration as a tool for optimization of metabolic stability and toxicity of drugs","volume":"1","author":"Kaur S.","year":"2017","journal-title":"Glob. J. Pharmaceut. Sci."},{"key":"e_1_2_10_11_1","first-page":"81","article-title":"The use of stable isotopes in pharmacological research","volume":"33","author":"Baillie T.A.","year":"1981","journal-title":"Pharmacol. Rev."},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1139\/y99-005"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/0378-5173(84)90057-7"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.8655"},{"key":"e_1_2_10_15_1","first-page":"35","article-title":"Two new drugs for tardive dyskinesia hit the market","volume":"27","author":"Morrow T.","year":"2018","journal-title":"Manag. Care"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e318263c443"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543776.2014.943184"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm4007998"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.56"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-011-9290-9"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(66)90031-1"}],"container-title":["Clinical and Translational Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fcts.12754","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.12754","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/cts.12754","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.12754","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T04:36:12Z","timestamp":1693888572000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1111\/cts.12754"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,10]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["10.1111\/cts.12754"],"URL":"https:\/\/doi.org\/10.1111\/cts.12754","archive":["Portico"],"relation":{},"ISSN":["1752-8054","1752-8062"],"issn-type":[{"value":"1752-8054","type":"print"},{"value":"1752-8062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,10]]},"assertion":[{"value":"2019-10-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-12-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-10","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}